For research use only. Not for therapeutic Use.
BET-IN-14 is an orally active pan BET inhibitor (IC50: 5.35 nM). BET-IN-14 has anti-cancer activity[1].
BET-IN-14 (Compound 171) (72 h) shows anti-tumor activity against various cancer cell lines (average IC50: 174.7 nM), especially in MM.1S, Ty-82, MV-4-11, and KG-1 cells[1].
BET-IN-14 (Compound 171) (50 and 100 mg/kg, p.o., qd) inhibits tumor growth in MV-4-11 xenograft[1]。
| Catalog Number | I041171 |
| CAS Number | 2243669-93-2 |
| Synonyms | (3R)-4-cyclopentyl-1,3-dimethyl-6-[2-(4-methylphenyl)-5-(4-methylpiperazine-1-carbonyl)-1,2,4-triazol-3-yl]-3H-quinoxalin-2-one |
| Molecular Formula | C30H37N7O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H37N7O2/c1-20-9-12-24(13-10-20)37-28(31-27(32-37)30(39)35-17-15-33(3)16-18-35)22-11-14-25-26(19-22)36(23-7-5-6-8-23)21(2)29(38)34(25)4/h9-14,19,21,23H,5-8,15-18H2,1-4H3/t21-/m1/s1 |
| InChIKey | RRASMEQGOOPKTF-OAQYLSRUSA-N |
| SMILES | CC1C(=O)N(C2=C(N1C3CCCC3)C=C(C=C2)C4=NC(=NN4C5=CC=C(C=C5)C)C(=O)N6CCN(CC6)C)C |
| Reference | [1]. Damaneh MS, et al. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Invest New Drugs. 2020 Jun;38(3):700-713. |
